MedTrace Logo

Vagal Blocking for Obesity Control

NCT00555958 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-02-02

No results posted yet for this study

Summary

To determine the safety, efficacy and treatment algorithm(s) of the Maestro System in causing weight loss in obese subjects - This study will provide feasibility data regarding the potential of intra-abdominal vagus nerve down-regulation/block in the treatment of obesity.

Conditions

Interventions

DEVICE

Active, implantable, intra-abdominal vagal blocking medical device

Intermittent, programmable, intra-abdominal vagal blocking

Sponsors & Collaborators

  • ReShape Lifesciences

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2011-09-30
Completion
2014-09-30

Countries

  • Australia
  • Mexico
  • Norway
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555958 on ClinicalTrials.gov